Michael Barbella, Managing Editor05.28.21
The global stem cell market is forecast to nearly double over the next seven years, growing 7.54 percent annually to reach $16.78 billion by 2028, according to a recent study by Market Study Report LLC. The sector was valued at $9.38 billion last year, the report indicates.
The report aims to get an overview of the stem cell market in terms of various factors. Growing awareness about umbilical cord stem cell, progression in stem cell research, and escalating demand for regenerative medicines are warranting global stem cell market growth. Moreover, technological advancements in this field, and risk of harmful immune reactions and complications are expected to present new growth opportunities in the upcoming years. Elaborating on the factors impeding global stem cell industry expansion, associated ethical concerns, high cost of stem cell procedures, and stringent regulations pertaining to therapeutic application will negatively impact business development during 2021-2028.
Asia Pacific
Asia Pacific's stem cell industry is slated to expand at an 8.14 percent compound annual growth rate (CAGR) through 2028, creditable to growing burden of chronic diseases like cancer, and large-scale investments towards medical research and healthcare facilities in developing economies. Further, increasing medical tourism in nations like India and China, together with positive economic outlook, and improving income in these nations are contributing to the regional market expansion. Besides, government efforts and investments in the field is expected to the boost the market share of APAC in the upcoming years.
Over the years, researchers have been contributing largely to the development of stem cell therapies in Japan. The stem cells have a substantial impact in treating terminal conditions, which encouraged researchers to contribute to this study field. Moreover, Japan is estimated to be among the prosperous countries in the stem cell market, with a significant focus on induced pluripotent stem cells as they hold high potential in regenerative medicines production. Additionally, the government has largely invested in stem cell R&D activities. Hence, these factors are likely to widen the scope and progress of the stem cell market across Japan.
Europe
Europe's stem cell market is estimated to swell 7.75 percent annually over the forecast timeline. Increasing R&D in the United Kingdom owing to presence of experts in developmental and reproduction biology coupled with a growing stem cell bank in the nation will contribute significantly to the industry growth in Europe. Moreover, expanding geriatric populace and increasing number of clinical trials in France has rendered a positive impact on the industry outlook.
There is a significant growth observed in France's geriatric population, which is expected to increase in the near future. This growth in the aging population is likely to offer several opportunities to the studied market. Moreover, several companies are enhancing their R&D activities, further motivating the market's progress. For instance, ECELL is involved in 20 research and innovation initiatives in cell-based therapy, developing cellular treatments based on the utilization of adult mesenchymal stem cells. Additionally, a large number of recruiting clinical trials were registered in the country across various phases of development linked with stem cell therapy for multiple symptoms. Thus, the R&D initiatives, along with the surge in the geriatric population, are projected to accelerate the stem cell market's progress in France.
North America
North America's stem cell market is slated to register a 7.41 percent CAGR over the projected timeline. This can be ascribed to proliferating number of cancer cases, presence of a well-established healthcare infrastructure, and burgeoning cases of Covid-19 in the U.S. Also, continuous R&D activities and high incidences of heart-related ailments in Canada is adding considerable momentum to the industry expansion.
In the United States, for instance, the number of cancer cases have proliferated, which has influenced leading companies to focus on R&D activities to initiate new stem cell therapies in treating such conditions. This contributes significantly to the evolution of the studied market. Additionally, the country has a well-established healthcare sector, with a large number of products set in line for stem cell therapies. Above all, several research activities are undertaken by market players to develop a treatment for limiting the spread of COVID-19. Thus, the rising R&D activities for developing novel cell therapies are likely to accelerate the stem cell market's progression across the United States.
Latin America
The Latin American stem cell market revenue share is expected to increase substantially, as the industry is touted to register 6.18 percent CAGR over the assessment period. Hefty investments in R&D, rising prevalence of lifestyle diseases, high rate of urinary tract infection due to multi-drug resistant bacteria, and subsequent surge in demand for stem cell therapies are expected to fuel the regional market growth in the upcoming years.
In the Rest of Latin America, several lifestyle-oriented diseases, such as diabetes, chronic kidney conditions, and obesity, are highly prevalent. Moreover, the countries in the region have observed a high rate of urinary tract infections, owing to multi-drug resistant bacteria. Here, since several of these countries are reliant on imports, investors are influenced to commence stem cell operations across the region. Therefore, these investments, along with the high prevalence of chronic conditions, increase the need for stem cell therapies, thereby augmenting the stem cell market?s progress in the Rest of Latin American region.
The worldwide gene editing market size is likely to record substantial growth in coming years owing to rising incidences of genetic disorders, ongoing development of advanced gene editing technologies, and high adoption of CRISPR technology. Gene editing or genome editing is group of technologies that gives scientist the capability to change DNA of an organism, including animals, bacteria, and plants. Editing DNA could further lead to changes in physical traits such as disease risk, and eye color. Scientist generally utilize different technologies to do this. These technologies, further allow the genetic material to be altered, removed or added at a specific place in the genome.
CRISPR-Cas9 is one of the most efficient and inexpensive system used for genome editing. The functions of CRISPR along with other related genes is important in adaptive immunity in selective archaea and bacteria. It further enables organism to respond to and remove any invading genetic material.
The report aims to get an overview of the stem cell market in terms of various factors. Growing awareness about umbilical cord stem cell, progression in stem cell research, and escalating demand for regenerative medicines are warranting global stem cell market growth. Moreover, technological advancements in this field, and risk of harmful immune reactions and complications are expected to present new growth opportunities in the upcoming years. Elaborating on the factors impeding global stem cell industry expansion, associated ethical concerns, high cost of stem cell procedures, and stringent regulations pertaining to therapeutic application will negatively impact business development during 2021-2028.
Asia Pacific
Asia Pacific's stem cell industry is slated to expand at an 8.14 percent compound annual growth rate (CAGR) through 2028, creditable to growing burden of chronic diseases like cancer, and large-scale investments towards medical research and healthcare facilities in developing economies. Further, increasing medical tourism in nations like India and China, together with positive economic outlook, and improving income in these nations are contributing to the regional market expansion. Besides, government efforts and investments in the field is expected to the boost the market share of APAC in the upcoming years.
Over the years, researchers have been contributing largely to the development of stem cell therapies in Japan. The stem cells have a substantial impact in treating terminal conditions, which encouraged researchers to contribute to this study field. Moreover, Japan is estimated to be among the prosperous countries in the stem cell market, with a significant focus on induced pluripotent stem cells as they hold high potential in regenerative medicines production. Additionally, the government has largely invested in stem cell R&D activities. Hence, these factors are likely to widen the scope and progress of the stem cell market across Japan.
Europe
Europe's stem cell market is estimated to swell 7.75 percent annually over the forecast timeline. Increasing R&D in the United Kingdom owing to presence of experts in developmental and reproduction biology coupled with a growing stem cell bank in the nation will contribute significantly to the industry growth in Europe. Moreover, expanding geriatric populace and increasing number of clinical trials in France has rendered a positive impact on the industry outlook.
There is a significant growth observed in France's geriatric population, which is expected to increase in the near future. This growth in the aging population is likely to offer several opportunities to the studied market. Moreover, several companies are enhancing their R&D activities, further motivating the market's progress. For instance, ECELL is involved in 20 research and innovation initiatives in cell-based therapy, developing cellular treatments based on the utilization of adult mesenchymal stem cells. Additionally, a large number of recruiting clinical trials were registered in the country across various phases of development linked with stem cell therapy for multiple symptoms. Thus, the R&D initiatives, along with the surge in the geriatric population, are projected to accelerate the stem cell market's progress in France.
North America
North America's stem cell market is slated to register a 7.41 percent CAGR over the projected timeline. This can be ascribed to proliferating number of cancer cases, presence of a well-established healthcare infrastructure, and burgeoning cases of Covid-19 in the U.S. Also, continuous R&D activities and high incidences of heart-related ailments in Canada is adding considerable momentum to the industry expansion.
In the United States, for instance, the number of cancer cases have proliferated, which has influenced leading companies to focus on R&D activities to initiate new stem cell therapies in treating such conditions. This contributes significantly to the evolution of the studied market. Additionally, the country has a well-established healthcare sector, with a large number of products set in line for stem cell therapies. Above all, several research activities are undertaken by market players to develop a treatment for limiting the spread of COVID-19. Thus, the rising R&D activities for developing novel cell therapies are likely to accelerate the stem cell market's progression across the United States.
Latin America
The Latin American stem cell market revenue share is expected to increase substantially, as the industry is touted to register 6.18 percent CAGR over the assessment period. Hefty investments in R&D, rising prevalence of lifestyle diseases, high rate of urinary tract infection due to multi-drug resistant bacteria, and subsequent surge in demand for stem cell therapies are expected to fuel the regional market growth in the upcoming years.
In the Rest of Latin America, several lifestyle-oriented diseases, such as diabetes, chronic kidney conditions, and obesity, are highly prevalent. Moreover, the countries in the region have observed a high rate of urinary tract infections, owing to multi-drug resistant bacteria. Here, since several of these countries are reliant on imports, investors are influenced to commence stem cell operations across the region. Therefore, these investments, along with the high prevalence of chronic conditions, increase the need for stem cell therapies, thereby augmenting the stem cell market?s progress in the Rest of Latin American region.
The worldwide gene editing market size is likely to record substantial growth in coming years owing to rising incidences of genetic disorders, ongoing development of advanced gene editing technologies, and high adoption of CRISPR technology. Gene editing or genome editing is group of technologies that gives scientist the capability to change DNA of an organism, including animals, bacteria, and plants. Editing DNA could further lead to changes in physical traits such as disease risk, and eye color. Scientist generally utilize different technologies to do this. These technologies, further allow the genetic material to be altered, removed or added at a specific place in the genome.
CRISPR-Cas9 is one of the most efficient and inexpensive system used for genome editing. The functions of CRISPR along with other related genes is important in adaptive immunity in selective archaea and bacteria. It further enables organism to respond to and remove any invading genetic material.